mycoplasma pneumonia

Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to mycoplasma pneumonia: viral pneumonia, Legionella pneumonia

mycoplasma pneumonia

A primary atypical pneumonia caused by Mycoplasma pneumoniae, which is associated with mini-epidemics that spread by aerosol or close contact to most individuals in closed populations (e.g., military boot camps, boarding schools, colleges), affecting those aged 5–20.
Clinical findings
Incubation ± 3 weeks; insidious onset of fever, malaise, headache, myalgia, low-grade fever, cough, chest pain and respiratory disease, from asymptomatic to rhinitis, pharyngitis, tracheobronchitis and pneumonia.

Leukocytosis, relative increase in PMNs, cold hemagglutinins, biologic false-positive VDRL.
Erythema multiforme, Raynaud’s disease, cold agglutinin haemolysis; less commonly, neurological, cardiovascular, musculoskeletal defects.
Tetracycline, erythromycin.

None currently available.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

mycoplasma pneumonia

Primary atypical pneumonia; walking pneumonia Infectious disease A primary atypical pneumonia by M pneumoniae, which causes miniepidemics that spread by aerosol or close contact, causing up to34 of a 'closed population'–military 'boot' camps, boarding schools, colleges–pneumonias, affecting ages 5-20 Clinical Incubation ± 3 wks; insidious onset of fever, malaise, headache, myalgia, low-grade fever, cough, chest pain, and respiratory disease from asymptomatic to rhinitis, pharyngitis, tracheobronchitis, pneumonia Lab Leukocytosis, relative ↑ in PMNs, cold hemagglutinins, biologic false positive VDRL Complications Erythema multiforme, Raynaud's phenomenon, cold agglutinin hemolysis; less commonly, neurologic, cardiovascular, musculoskeletal defects Treatment Tetracycline, erythromycin Vaccine Under development
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

Mycoplasma pneumonia

An incomplete bacterium that infects the lung.
Mentioned in: Erythema Multiforme
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Chen, "The clinical characteristics and predictors of refractory Mycoplasma pneumonia pneumonia in children," PLoS One, vol.
Considering that mycoplasma pneumonia is a self-limiting disease, nasal high-flow oxygen therapy can be a good indication for those with severe mycoplasma pneumonia.
The specimens were then prepared for qLAMP using a set of specific primers for Streptococcus pneumonia (SP), Staphylococcus aureus (SA), Escherichia coli (EC), Klebsiella pneumonia (KP), Pseudomonas aeruginosa (PA), Acinetobacter baumannii (AB), Stenotrophomonas maltophilia (SM), Haemophilus influenzae (HI), Legionella pneumophila (LP), Mycoplasma pneumonia (MP), and Chlamydophila pneumoniae (CP).
The diagnosis of Erythema Multiforme should be based on the clinical signs, symptoms, and a thorough patient medical history and it is highly linked with herpes virus or mycoplasma pneumonia infections or can be drug induced erythema multiforme.
To date, the pathogenesis of Mycoplasma pneumonia has not clear yet; the main pathogenesis tends to be adhesion and penetration of MP, direct injury to cells, and inflammation reaction [10].
Mycoplasma pneumonia is contagious disease of young adult and children caused by mycoplasma pneumoniae, it's characterized by 9-12 days incubation period and followed by a symptoms of an upper respiratory infection.
It can also be the result of infection by mycoplasma pneumonia, legionella or certain viral respiratory infections.
Renier Pistorius joins BIVI swine division as the Sr Brand Mgr for its mycoplasma pneumonia vaccine, Ingelvac MycoFLEX.
The third edition adds entries on new vaccines and viruses, defensins, food safety, mycoplasma pneumonia, and neonatal infections.
(25) While bacterial and Mycoplasma pneumonia can be treated with antibiotics, there is no treatment for viral pneumonia.
Gemifloxacin, an oral broad-spectrum fluoroquinolone marketed as Factive by Oscient Pharmaceuticals, was approved in 2003 for treating mild to moderate community-acquired pneumonia (CAP) due to Streptococcus pneumoniae (including multidrug-resistant strains), Hemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumonia, Chlamydia pneumonia, and Klebsiella pneumoniae and for treating acute bacterial exacerbations of chronic bronchitis (ABECB) due to S.